Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
NCT05046613 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 780
Last updated 2026-05-05
Summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Conditions
Interventions
- OTHER
-
Rimegepant
75mg
- OTHER
-
Not taking Rimegepant
No rimegepant
Sponsors & Collaborators
-
PPD, Part of Thermo Fisher Scientific
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 0 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-23
- Primary Completion
- 2029-11-04
- Completion
- 2034-04-30
Countries
- United States
Study Locations
More Related Trials
-
Aimovig Pregnancy Exposure Registry
NCT06150781 ·Status: RECRUITING
-
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865 ·Status: COMPLETED ·Phase: PHASE4
-
Sumatriptan and Naratriptan Pregnancy Registry
NCT01059604 ·Status: COMPLETED
-
Consistency of Response With Rimegepant in Acute Treatment of Migraine
NCT06898047 ·Status: ACTIVE_NOT_RECRUITING
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400 ·Status: COMPLETED ·Phase: PHASE4
-
Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg
NCT05888766 ·Status: UNKNOWN
-
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927 ·Status: COMPLETED ·Phase: PHASE4
-
Acute Migraine Treatment in the ED With Gepants
NCT06985342 ·Status: TERMINATED ·Phase: PHASE4
-
Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
NCT07301008 ·Status: RECRUITING ·Phase: PHASE4
-
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
NCT05158894 ·Status: RECRUITING
-
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
NCT06532357 ·Status: COMPLETED
-
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
NCT05810038 ·Status: COMPLETED ·Phase: PHASE3
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
Cluster Headache Treatment With Rimegepant
NCT05264714 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Nerivio in Pregnant Women With Migraine
NCT05464069 ·Status: COMPLETED
-
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
NCT05399459 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Safety Study in Acute Treatment of Migraine
NCT03266588 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)
NCT05399485 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
NCT00806546 ·Status: COMPLETED ·Phase: PHASE3
-
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
NCT05854992 ·Status: COMPLETED
-
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
NCT06680206 ·Status: COMPLETED
-
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
NCT00792103 ·Status: COMPLETED ·Phase: PHASE3